JP Morgan Initiates Coverage On Kura Oncology with Overweight Rating, Announces Price Target of $30

Benzinga Newsdesk www.benzinga.com Neutral 72.9%

Neg 0% Neu 72.9% Pos 0%

JP Morgan analyst Priyanka Grover initiates coverage on Kura Oncology (NASDAQ:KURA) with a Overweight rating and announces Price Target of $30.